EP1185265A4 - IL-8 RECEPTOR ANTAGONISTS - Google Patents

IL-8 RECEPTOR ANTAGONISTS

Info

Publication number
EP1185265A4
EP1185265A4 EP00941455A EP00941455A EP1185265A4 EP 1185265 A4 EP1185265 A4 EP 1185265A4 EP 00941455 A EP00941455 A EP 00941455A EP 00941455 A EP00941455 A EP 00941455A EP 1185265 A4 EP1185265 A4 EP 1185265A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00941455A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1185265A1 (en
Inventor
Gregory M Benson
Melvin Clarence Rutledge
Katherine L Widdowson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1185265A1 publication Critical patent/EP1185265A1/en
Publication of EP1185265A4 publication Critical patent/EP1185265A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00941455A 1999-06-16 2000-06-15 IL-8 RECEPTOR ANTAGONISTS Withdrawn EP1185265A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14002499P 1999-06-16 1999-06-16
US140024P 1999-06-16
PCT/US2000/016506 WO2000076501A1 (en) 1999-06-16 2000-06-15 Il-8 receptor antagonists

Publications (2)

Publication Number Publication Date
EP1185265A1 EP1185265A1 (en) 2002-03-13
EP1185265A4 true EP1185265A4 (en) 2004-02-04

Family

ID=22489379

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00941455A Withdrawn EP1185265A4 (en) 1999-06-16 2000-06-15 IL-8 RECEPTOR ANTAGONISTS

Country Status (19)

Country Link
EP (1) EP1185265A4 (es)
JP (1) JP2003501463A (es)
KR (1) KR20020015347A (es)
CN (1) CN1356899A (es)
AR (1) AR024350A1 (es)
AU (1) AU766235B2 (es)
BR (1) BR0011122A (es)
CA (1) CA2377386A1 (es)
CO (1) CO5190696A1 (es)
CZ (1) CZ20014472A3 (es)
HU (1) HUP0201582A3 (es)
IL (1) IL145762A0 (es)
MX (1) MXPA01013005A (es)
NO (1) NO20016052D0 (es)
NZ (1) NZ514696A (es)
PL (1) PL352213A1 (es)
TR (1) TR200103638T2 (es)
WO (1) WO2000076501A1 (es)
ZA (1) ZA200109480B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE422203T1 (de) 2002-10-09 2009-02-15 Schering Corp Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden
DE10334309A1 (de) * 2003-07-28 2005-03-03 Aventis Pharma Deutschland Gmbh Substituierte Thiazol-Benzoisothiazoldioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
US7442709B2 (en) 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
AU2004268949A1 (en) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl C-kit inhibitors
AP2006003553A0 (en) 2003-08-21 2006-04-30 Osi Pharm Inc N-substituted pyrazolyl-amidyl-benzimidazolyl C- kit inhibitors.
MXPA06007076A (es) 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Tiadiazoles como ligandos del receptor cxc y cc-quimiocina.
JP2008517930A (ja) 2004-10-21 2008-05-29 トランス テック ファーマ,インコーポレイテッド GalR1のアゴニストとしてのビススルホンアミド化合物、組成物、及び使用法
US7419995B2 (en) 2004-12-01 2008-09-02 Osi Pharmaceuticals, Inc. N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library
BR112012003462A2 (pt) 2009-08-24 2016-02-23 Ascepion Pharmaceuticals Inc "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
CN102060780B (zh) * 2010-12-27 2014-11-05 雅本化学股份有限公司 2-(n-取代)-氨基苯并咪唑衍生物的制备方法
CN111116502A (zh) * 2018-10-30 2020-05-08 中国石油化工股份有限公司 一步法合成苯骈三氮唑的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032439A1 (en) * 1997-01-23 1998-07-30 Smithkline Beecham Corporation Il-8 receptor antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032439A1 (en) * 1997-01-23 1998-07-30 Smithkline Beecham Corporation Il-8 receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOWARD O M Z ET AL: "CHEMOKINES: PROGRESS TOWARD IDENTIFYING MOLECULAR TARGETS FOR THERAPEUTIC AGENTS", TRENDS IN BIOTECHNOLOGY, ELSEVIER, AMSTERDAM,, GB, vol. 14, February 1996 (1996-02-01), pages 46 - 51, XP002919059, ISSN: 0167-7799 *
See also references of WO0076501A1 *

Also Published As

Publication number Publication date
CA2377386A1 (en) 2000-12-21
HUP0201582A2 (hu) 2002-12-28
TR200103638T2 (tr) 2002-04-22
KR20020015347A (ko) 2002-02-27
CN1356899A (zh) 2002-07-03
WO2000076501A1 (en) 2000-12-21
MXPA01013005A (es) 2002-07-02
AU766235B2 (en) 2003-10-09
IL145762A0 (en) 2002-07-25
JP2003501463A (ja) 2003-01-14
HUP0201582A3 (en) 2003-02-28
NO20016052L (no) 2001-12-11
AU5616100A (en) 2001-01-02
EP1185265A1 (en) 2002-03-13
BR0011122A (pt) 2002-02-26
NO20016052D0 (no) 2001-12-11
CO5190696A1 (es) 2002-08-29
CZ20014472A3 (cs) 2002-06-12
ZA200109480B (en) 2002-11-18
PL352213A1 (en) 2003-08-11
AR024350A1 (es) 2002-10-02
NZ514696A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
IL145761A0 (en) Il-8 receptor antagonists
DZ3309A1 (en) Il-8 receptor antagonists
AU4560601A (en) Il-8 receptor antagonists
IL145762A0 (en) Il-8 receptor antagonists
PL351946A1 (en) Il-8 receptor antagonists
AP2002002599A0 (en) Il-8 receptor antagonists
PL351947A1 (en) Il-8 receptor antagonists
EP1047424A4 (en) IL-8 RECEPTOR ANTAGONISTS
EP1039903A4 (en) INTERLEUKIN-8 RECEPTOR ANTAGONISTS
HK1044717A1 (zh) Il-8受體拮抗劑
EP1261329A4 (en) IL-8 RECEPTOR ANTAGONISTS
HK1044475A1 (zh) Il-8受體拮抗劑
IL146214A0 (en) Il-8 receptor antagonists
IL146515A0 (en) Il-8 receptor antagonists
IL140983A0 (en) Il-8 receptor antagonists
EP1237548A4 (en) IL-8 RECEPTOR ANTAGONISTS
ZA985813B (en) IL-8 receptor antagonists
ZA985975B (en) IL-8 receptor antagonists
EP1121360A4 (en) INTERLEUKIN-8 (IL-8) RECEPTOR ANTAGONISTS
EP1087661A4 (en) IL-8 RECEPTOR ANTAGONISTS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI PAYMENT 20011108

A4 Supplementary search report drawn up and despatched

Effective date: 20031229

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/4184 A

Ipc: 7A 61K 31/4192 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040309

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1044474

Country of ref document: HK